---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-100847"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-10-21T23:59:59+00:00"
generated_at: "2026-05-17T03:00:33.850276+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Pharmaceuticals raises $6.0M in registered direct offering for LYMPHIR launch

## Summary
- Gross proceeds ~$6.0M; net ~$5.5M after placement agent fees and expenses.
- Offering: 3,973,510 shares/pre-funded warrants plus 3,973,510 common warrants at $1.51/share.
- Common warrants exercisable at $1.40/share, 5-year term; pre-funded warrants at $0.0001/share.
- Net proceeds to support commercial launch of LYMPHIR™ and other product candidates.
- H.C. Wainwright acted as placement agent; 7.0% cash fee and 278,146 placement agent warrants.

## SEC filing metadata
- accession: 0001213900-25-100847
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-10-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025100847/0001213900-25-100847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025100847/ea0261909-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-100847
- JSON: https://secwatch.observer/filing/0001213900-25-100847.json
- Plain text: https://secwatch.observer/filing/0001213900-25-100847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.